When nothing has worked: the people turning to natural and complementary therapies
For millions living with long-term conditions, another prescription feels like another dead end. Here is what they are trying instead, and what the evidence actually supports.
Latest
- SubstancesThe psychedelic research boom, and what it doesn’t prove yet
- MoneyThe house edge is the only number that matters
- MoneyBuy now, pay later: the loan that doesn’t feel like one
- MoneyThe exclusions page is where your policy actually lives
- LongevityWhen “natural” isn’t regulated: how to read a supplement label
Pick your poison.
How money really works: credit, debt, tax, insurance and gambling, and the fine print that quietly costs you.
Money →Health, ageing & the evidenceLiving longer and living better: supplements, alternative therapies and health trends, tested against the evidence.
Longevity →Drugs, policy & harm reductionClear-eyed reporting on drugs: the science, the law, the culture and how to stay safer. No moralising, no glamorising.
Substances →Ideas for living deliberatelyOld ideas for modern problems: risk, desire, discipline, meaning, and how to think clearly about the choices nobody teaches you to make.
Philosophy →Read these first.
The psychedelic research boom, and what it doesn’t prove yet
Clinical trials have made psilocybin respectable again, and a US approval may be close. Read past the headlines and the evidence is more careful than the hype.
Buy now, pay later: the loan that doesn’t feel like one
Split payments look like a checkout feature. They are credit, and since July 2026 they are regulated credit, but the protections have gaps and the costs still show up in places you might not expect.
When “natural” isn’t regulated: how to read a supplement label
Most supplements in the UK are sold as food, not medicine. That changes what the label must show, what it is allowed to promise, and what nobody had to prove.
Everything, newest first.
When nothing has worked: the people turning to natural and complementary therapies
For millions living with long-term conditions, another prescription feels like another dead end. Here is what they are trying instead, and what the evidence actually supports.
The psychedelic research boom, and what it doesn’t prove yet
Clinical trials have made psilocybin respectable again, and a US approval may be close. Read past the headlines and the evidence is more careful than the hype.
The house edge is the only number that matters
Bonuses, streaks and systems are noise. Every casino game is built on one figure, it is published, and it always points the same way.
Buy now, pay later: the loan that doesn’t feel like one
Split payments look like a checkout feature. They are credit, and since July 2026 they are regulated credit, but the protections have gaps and the costs still show up in places you might not expect.
The exclusions page is where your policy actually lives
The headline cover sells the policy. The exclusions decide whether you get paid, and UK rules give you more protection than most people realise.
When “natural” isn’t regulated: how to read a supplement label
Most supplements in the UK are sold as food, not medicine. That changes what the label must show, what it is allowed to promise, and what nobody had to prove.
Drug checking, explained: the case for testing over guessing
Pills and powders are often not what they are sold as. Drug checking services tell people what is actually in them. Here is how they work, what the UK evidence shows and where the law stands.
Crypto’s tax trail is longer than you think
Swapping one coin for another can be a taxable event, and from 2026 exchanges report UK customers’ details to HMRC. Many people only find out when the letter arrives.
Loot boxes, skins and the blurry line into betting
Paying real money for a random reward looks a lot like gambling. In Britain the law mostly says it is not, but betting with the skins those boxes produce is a different matter.